NAL Pharma is a specialty drug developer that focuses on creating novel dosage forms and proprietary drug delivery systems. They utilize their own captive proprietary Drug Delivery System (DDS) technologies, including Bio-D3, Bio-FX, Bio-CR, Bio-NN, and Bio-MM, to develop innovative drug dosage forms and delivery systems. Their technologies range from transdermal patches and fast-onset orally-dissolving films to controlled-release oral and injectable DDS options.

NAL Pharma's main goals are to improve patient compliance, safety, and efficacy while enhancing the overall quality of pharmaceutical products. They achieve this by converting patent-expiring blockbuster drugs into new DDS formats with improved features. Additionally, they collaborate with major pharmaceutical companies to advance the drug delivery systems of their new drug entities and improve existing formulations.

As a privately owned corporation headquartered in Hong Kong, NAL Pharma works in partnership with international pharmaceutical development laboratories and manufacturing operations across Asia and Europe. This allows them to expedite the product development and commercialization of their innovative drug delivery systems in global markets